The prognostic impact of tet oncogene family member 2 mutations in patients with acute myeloid leukemia: a systematic-review and meta-analysis

{BackgroundThe impact of Tet oncogene family member 2 (TET2) mutations on the prognosis of acute myeloid leukemia (AML) is still controversial. A meta analysis is needed in order to assess the prognostic significance of TET2 mutation in AML.MethodsFive databases including PubMed, Cochrane, EMBase, China National Knowledge Internet (CNKI) and Wanfang database were retrieved to search studies that investigated the correlation between TET2 mutations and outcomes of AML patients. Pooled hazard ratios (HRs) and odds ratios (ORs) were used to assess the effects of TET2 mutations.ResultsSixteen studies were included. TET2 mutation was an unfavorable prognostic factor for overall survival (OS: HR=1.386; P<0.001) and event-free survival (EFS: HR=1.594; P=0.002) in patients with AML. For patients under 65years of age, TET2 mutation predicted an inferior OS (HR=1.310